BEONE MEDICINES LTD. (ONC) FY2026 Q2 Statement of Cash Flows
2026-04-01 to 2026-06-30
Statement of Cash Flows
2026-04-01 to 2026-06-30
Swipe to see the full flow
Chart details
BEONE MEDICINES LTD. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026
Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Mar 31, 2026
- 4,853,425,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- Operating activities
- 462,820,000 US dollars. Net cash provided. The remaining amount is calculated by subtracting the other displayed items from the operating total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Non-cash interest expense), so Acquired in-process research and development cannot be separated for this quarter. It may combine inflows and outflows.
- Net income
- 237,007,000 US dollars
- Depreciation and amortization expense
- 40,515,000 US dollars
- Share-based compensation expenses
- 137,405,000 US dollars
- Amortization of research and development cost share liability
- negative 29,518,000 US dollars
- Other items, net
- 8,240,000 US dollars
- Accounts receivable
- negative 117,576,000 US dollars
- Inventories
- negative 47,150,000 US dollars
- Other assets
- negative 11,377,000 US dollars
- Accounts payable
- 37,530,000 US dollars
- Accrued expenses and other payables
- 212,435,000 US dollars
- Other liabilities
- negative 4,113,000 US dollars
- Remaining operating cash flows, net (calculated)
- negative 578,000 US dollars
- Investing activities
- negative 49,353,000 US dollars. Net cash used.
- Purchases of property, plant and equipment
- negative 27,476,000 US dollars
- Purchase of intangible assets
- 0 US dollars
- Proceeds from sale or maturity of investments
- 5,845,000 US dollars
- Purchase of in-process research and development
- negative 20,518,000 US dollars
- Other investing activities
- negative 7,204,000 US dollars
- Financing activities
- negative 6,054,000 US dollars. Net cash used.
- Repayment of long-term loan
- negative 17,052,000 US dollars
- Proceeds from short-term loans
- 0 US dollars
- Repayment of short-term loans
- 0 US dollars
- Repayment of sale of future royalties liability
- 1,000 US dollars
- Payments of withholding taxes from share-based awards
- 0 US dollars
- Proceeds from option exercises and employee share purchase plan
- 11,048,000 US dollars
- Other financing activities
- negative 51,000 US dollars
- Operating adjustment reconciliation
- 436,125,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
- financing gross reconciliation
- 17,103,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing gross reconciliation
- 55,198,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- Exchange-rate effect
- 19,836,000 US dollars
- Ending cash on Jun 30, 2026
- 5,280,674,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- Cash sources and uses
- 5,336,081,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- 427,249,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- 1.95×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- Operating cash flow
- 462,820,000 US dollars. Operating cash flow used in the free cash flow calculation.
- Cash purchases of property, plant and equipment
- 27,476,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- 435,344,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $225.81M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 462,820,000 US dollars minus 27,476,000 US dollars equals 435,344,000 US dollars.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!